{"id":14407,"date":"2012-11-07T09:36:17","date_gmt":"2012-11-07T08:36:17","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=14407"},"modified":"2021-09-22T09:39:18","modified_gmt":"2021-09-22T07:39:18","slug":"cobo-m-de-castro-j-isla-d-lozano-v-oyaguez-i-castro-gomez-aj","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/cobo-m-de-castro-j-isla-d-lozano-v-oyaguez-i-castro-gomez-aj\/","title":{"rendered":"Cobo M, De Castro J, Isla D, Lozano V, Oyag\u00fcez I, Castro-Gomez AJ"},"content":{"rendered":"<div class=\"col80\">\n<p class=\"miniatura_foto\" style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-14157 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/ISPOR.jpg\" alt=\"\" width=\"120\" height=\"120\" \/>Cobo M, De Castro J, Isla D, Lozano V, Oyag\u00fcez I, Castro-Gomez AJ<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<div class=\"col80p\">\n<h6 style=\"text-align: justify;\">Cost-effectiveness of erlotinib as first-line maintenance therapy for advanced non-small-cell lung carcinoma in patients EGFR WT and stable disease after four cycles of chemotherapy<\/h6>\n<h6 style=\"text-align: justify;\"><strong>15th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov 2012<\/strong><\/h6>\n<p><a href=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/09\/103.pdf\" target=\"_blank\" rel=\"noopener\">POSTER<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cobo M, De Castro J, Isla D, Lozano V, Oyag\u00fcez I, Castro-Gomez AJ &nbsp; &nbsp; Cost-effectiveness of erlotinib as first-line maintenance therapy for advanced non-small-cell lung carcinoma in patients EGFR WT and stable disease after four cycles of chemotherapy 15th Annual European Congress International Society for Pharmacoeconomics &amp; Outcomes Research (ISPOR). Berlin, Germany. 3-7 nov&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/cobo-m-de-castro-j-isla-d-lozano-v-oyaguez-i-castro-gomez-aj\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[116,928,246],"tags":[],"class_list":["post-14407","post","type-post","status-publish","format-quote","hentry","category-ace-acu-tipo-de-proyecto","category-oncologia","category-international-society-of-pharmacoeconomics-and-outcomes-research","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14407"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=14407"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14407\/revisions"}],"predecessor-version":[{"id":14409,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/14407\/revisions\/14409"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=14407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=14407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=14407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}